New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer

Simple Summary A new methodology of cancer testing, called “liquid biopsy”, has been under investigation in the past few years. It is based on blood tests that can be analyzed by novel genetics and bioinformatics tools, in order to detect cancer, predict or follow the response to therapies and understand the mechanisms of relapse. This technology is still experimental, yet it has sparked much interest within the scientific community because it promises a new era of cancer management. We here review its application in a subset of tumors characterized by the presence of the ALK oncogene: patients affected by these tumors can benefit from targeted therapy, but show frequent relapses, which call for improved methods of disease detection. Abstract Cancer cells are characterized by high genetic instability, that favors tumor relapse. The identification of the genetic causes of relapse can direct next-line therapeutic choices. As tumor tissue rebiopsy at disease progression is not always feasible, noninvasive alternative methods are being explored. Liquid biopsy is emerging as a non-invasive, easy and repeatable tool to identify specific molecular alterations and monitor disease response during treatment. The dynamic follow-up provided by this analysis can provide useful predictive information and allow prompt therapeutic actions, tailored to the genetic profile of the recurring disease, several months before radiographic relapse. Oncogenic fusion genes are particularly suited for this type of analysis. Anaplastic Lymphoma Kinase (ALK) is the dominant driver oncogene in several tumors, including Anaplastic Large-Cell Lymphoma (ALCL), Non-Small Cell Lung Cancer (NSCLC) and others. Here we review recent findings in liquid biopsy technologies, including ctDNA, CTCs, exosomes, and other markers that can be investigated from plasma samples, in ALK-positive cancers.

[1]  D. Planchard,et al.  Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors , 2021, npj Precision Oncology.

[2]  O. Delattre,et al.  Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Tombolan,et al.  Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor , 2021, Frontiers in Pediatrics.

[4]  M. Pillon,et al.  Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges , 2021, Cancers.

[5]  T. Leblanc,et al.  Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease? , 2021, Pediatric blood & cancer.

[6]  M. Lim,et al.  Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1 , 2021, Blood.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  C. Marquette,et al.  Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Bortoluzzi,et al.  Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers? , 2021, Diagnostics.

[10]  A. Iolascon,et al.  A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma , 2020, Frontiers in Oncology.

[11]  P. Brousset,et al.  Minimal residual disease monitoring using a 3'ALK universal probe assay in ALK-positive anaplastic large cell lymphoma: ddPCR, an attractive alternative method to real-time quantitative PCR. , 2020, The Journal of molecular diagnostics : JMD.

[12]  A. Stenzinger,et al.  Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA , 2020, EBioMedicine.

[13]  U. Tateishi,et al.  Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial , 2020, Cancer science.

[14]  E. Sokol,et al.  1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses , 2020 .

[15]  M. Fischer,et al.  Multiplexed quantification of four neuroblastoma DNA targets in a single droplet digital PCR reaction. , 2020, The Journal of molecular diagnostics : JMD.

[16]  Xue Wu,et al.  Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report , 2020, Frontiers in Oncology.

[17]  C. Marquette,et al.  Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. , 2020, The Lancet. Respiratory medicine.

[18]  B. Klaeser,et al.  Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC , 2020, Case Reports in Oncology.

[19]  K. O'Byrne,et al.  The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells , 2020, Cells.

[20]  J. Ahn,et al.  Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors. , 2020 .

[21]  K. Basso,et al.  miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma , 2020, Haematologica.

[22]  D. Planchard,et al.  Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. , 2020, JCO precision oncology.

[23]  P. Meldgaard,et al.  Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients , 2020, Cancers.

[24]  Xue Wu,et al.  Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis , 2020, Cancer science.

[25]  V. Calvo,et al.  Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report , 2020, Translational lung cancer research.

[26]  S. Bortoluzzi,et al.  RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player? , 2020, Frontiers in Oncology.

[27]  T. Heike,et al.  Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma. , 2020, Journal of pediatric hematology/oncology.

[28]  A. Stenzinger,et al.  Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer , 2019, Cold Spring Harbor molecular case studies.

[29]  A. Shaw,et al.  ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-positive NSCLC: Pooled Analysis of Two Prospective Trials. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  H. Wakelee,et al.  Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  William H. Bisson,et al.  A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  W. Klapper,et al.  Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma , 2019, Haematologica.

[33]  A. Grothey,et al.  Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay , 2019, JCO precision oncology.

[34]  Y. Kukita,et al.  Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment , 2019, PloS one.

[35]  D. Planchard,et al.  Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer , 2019, Clinical Cancer Research.

[36]  H. Hosoi,et al.  A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients. , 2019, Japanese journal of clinical oncology.

[37]  C. Paweletz,et al.  Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. , 2019, Lung cancer.

[38]  A. Shaw,et al.  Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity , 2019, Clinical Cancer Research.

[39]  N. Pavlakis,et al.  Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  I. Oh,et al.  Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer , 2019, Journal of Cancer Research and Clinical Oncology.

[41]  Xiaoyan Zhou,et al.  The role of exosomal shuttle RNA (esRNA) in lymphoma. , 2019, Critical reviews in oncology/hematology.

[42]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[43]  G. Mills,et al.  Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  A. Shaw,et al.  ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. O'Byrne,et al.  Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets , 2019, Cancers.

[46]  K. Pantel,et al.  Liquid biopsy and minimal residual disease — latest advances and implications for cure , 2019, Nature Reviews Clinical Oncology.

[47]  E. Felip,et al.  Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[49]  C. Rolfo,et al.  EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy , 2018, Translational cancer research.

[50]  Haitao Zhao,et al.  Liquid biopsy in tumors: opportunities and challenges. , 2018, Annals of translational medicine.

[51]  S. Joosse,et al.  Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management , 2018, Computational and structural biotechnology journal.

[52]  P. Brousset,et al.  miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells , 2018, Haematologica.

[53]  Dan Sun,et al.  Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer , 2018, Molecular Cancer.

[54]  Paul Baas,et al.  Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  D. Enderle,et al.  Exosome liquid biopsies of NSCLC patients for longitudinal monitoring of ALK fusions and resistance mutations. , 2018 .

[56]  P. Ceppi,et al.  Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma , 2018, Oncotarget.

[57]  P. Saintigny,et al.  Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients. , 2018 .

[58]  Benjamin P Towler,et al.  Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine , 2018, Biomolecules.

[59]  O. Pös,et al.  Circulating cell-free nucleic acids: characteristics and applications , 2018, European Journal of Human Genetics.

[60]  Kenneth L. Jones,et al.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[61]  Wenchen Pu,et al.  Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer , 2018, Cell Research.

[62]  A. Shaw,et al.  Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[63]  C. Paweletz,et al.  Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  M. Lim,et al.  Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond , 2018, Cancers.

[65]  Ximing J. Yang,et al.  Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib , 2018, Clinical Cancer Research.

[66]  E. Patrucco,et al.  Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes , 2018, Cancers.

[67]  K. Horibe,et al.  Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma , 2018, International Journal of Hematology.

[68]  Markus Riester,et al.  Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. , 2018, JCO precision oncology.

[69]  Wenjie Guo,et al.  The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor , 2017, Cancer management and research.

[70]  C. Marquette,et al.  Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France , 2017, BMJ Open.

[71]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer discovery.

[72]  A. Facchinetti,et al.  Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. , 2017, Journal of thoracic disease.

[73]  M. Lim,et al.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  M. Fischer,et al.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma , 2017, Oncotarget.

[75]  Majid E Warkiani,et al.  Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device , 2017, Oncotarget.

[76]  M. Erlander,et al.  Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  R. Kurzrock,et al.  Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma , 2017, Clinical Cancer Research.

[78]  Hecheng Zhou,et al.  CircRNA: functions and properties of a novel potential biomarker for cancer , 2017, Molecular Cancer.

[79]  D. Planchard,et al.  Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. , 2017, Cancer research.

[80]  P. V. Van Schil,et al.  Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. , 2017, Lung cancer.

[81]  Min Zhang,et al.  Circulating microRNAs as novel biomarkers of ALK-positive non-small cell lung cancer and predictors of response to crizotinib therapy , 2017, Oncotarget.

[82]  N. Rosenfeld,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[83]  N. Palanisamy,et al.  Expanded Circulating Tumor Cells from a Patient with ALK‐Positive Lung Cancer Present with EML4‐ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[84]  Huimin Wang,et al.  Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer , 2016, Oncotarget.

[85]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.

[86]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[87]  A. Facchinetti,et al.  Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC). , 2016, Clinical lung cancer.

[88]  S. Chuai,et al.  Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing , 2016, Oncotarget.

[89]  D. Atanackovic,et al.  Characterization of different CTC subpopulations in non-small cell lung cancer , 2016, Scientific Reports.

[90]  P. Pandolfi,et al.  Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations , 2016, Cell.

[91]  F. Wang,et al.  Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy , 2016, Oncotarget.

[92]  Y. W. Chua,et al.  Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer , 2016, Oncotarget.

[93]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[94]  P. Pauwels,et al.  Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice , 2016, Oncotarget.

[95]  Meng Xu,et al.  The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10. , 2016, Oncology letters.

[96]  Pieter Wesseling,et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics , 2015, Cancer cell.

[97]  E. Smit,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[98]  Geoffrey R. Oxnard,et al.  Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients , 2015, Clinical Cancer Research.

[99]  Tina Koestler,et al.  Abstract 545: Plasma-based diagnostics for detection of EML4-ALK fusion transcripts in NSCLC patients , 2015 .

[100]  Jiang-xia Zhao,et al.  Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis , 2015, Cell Research.

[101]  Junji Uchida,et al.  High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients , 2015, DNA research : an international journal for rapid publication of reports on genes and genomes.

[102]  Feng Jiang,et al.  Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer , 2015, Laboratory Investigation.

[103]  Massimo Bellomi,et al.  miR-Test: a blood test for lung cancer early detection. , 2015, Journal of the National Cancer Institute.

[104]  Suzanne D Turner,et al.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation , 2015, The Journal of pathology.

[105]  J. Blay,et al.  Detection of tumor ALK status in neuroblastoma patients using peripheral blood , 2015, Cancer medicine.

[106]  L. Vella.  The Emerging Role of Exosomes in Epithelial–Mesenchymal-Transition in Cancer , 2014, Front. Oncol..

[107]  Marius Ilie,et al.  “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease , 2014, PloS one.

[108]  Jayoung Kim,et al.  Extracellular vesicles shed from gefitinib‐resistant nonsmall cell lung cancer regulate the tumor microenvironment , 2014, Proteomics.

[109]  Ed Yong,et al.  Cancer biomarkers: Written in blood , 2014, Nature.

[110]  N. Girard,et al.  Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.

[111]  A. Majid,et al.  Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. , 2014, Lung cancer.

[112]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  L. Guerra,et al.  Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. , 2014, Journal of the National Cancer Institute.

[115]  W. Jiang,et al.  Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes , 2014, Oncogene.

[116]  W. Klapper,et al.  Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. , 2014, Blood.

[117]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[118]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[119]  Alissa M. Weaver,et al.  Exosome secretion is enhanced by invadopodia and drives invasive behavior. , 2013, Cell reports.

[120]  E. Yamaoka,et al.  Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma , 2013, Pediatric Surgery International.

[121]  D. Planchard,et al.  Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  F. Speleman,et al.  MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells , 2013, Oncogene.

[123]  M. Pillon,et al.  Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis , 2013, Leukemia.

[124]  A. Richardson,et al.  Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. , 2012, Cancer discovery.

[125]  R. Coffey,et al.  Proteomic Analysis of Exosomes from Mutant KRAS Colon Cancer Cells Identifies Intercellular Transfer of Mutant KRAS* , 2012, Molecular & Cellular Proteomics.

[126]  C. Marquette,et al.  ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[127]  K. Savage,et al.  Anaplastic large cell lymphoma, ALK-positive. , 2012, Critical reviews in oncology/hematology.

[128]  H. Ji,et al.  The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers , 2012, Clinical Cancer Research.

[129]  L. Mologni.  Inhibitors of the anaplastic lymphoma kinase , 2012, Expert opinion on investigational drugs.

[130]  P. Laurent-Puig,et al.  Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. , 2012, Lung cancer.

[131]  F. Sánchez‐Madrid,et al.  Intercellular communication: diverse structures for exchange of genetic information , 2012, Nature Reviews Molecular Cell Biology.

[132]  A. Shaw,et al.  Crizotinib and testing for ALK. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[133]  T. Wurdinger,et al.  Blood platelets contain tumor-derived RNA biomarkers. , 2011, Blood.

[134]  Hyojin Kim,et al.  Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[135]  T. Molina,et al.  Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker , 2010, Clinical Cancer Research.

[136]  M. Weyant,et al.  Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer , 2010, Clinical and translational science.

[137]  R. Greil,et al.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma , 2010, Proceedings of the National Academy of Sciences of the United States of America.

[138]  A. Iafrate,et al.  A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[139]  A. Puisieux,et al.  Influence of neuroblastoma stage on serum‐based detection of MYCN amplification , 2009, Pediatric blood & cancer.

[140]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[141]  P. Jänne,et al.  Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[142]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[143]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[144]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[145]  Yun-fei Shi,et al.  [Anaplastic lymphoma kinase gene abnormality and the expression of its fusion protein in primary systemic anaplastic large cell lymphoma]. , 2008, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[146]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[147]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[148]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[149]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[150]  A. Reiter,et al.  Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction , 2007, British journal of haematology.

[151]  W. Klapper,et al.  Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. , 2007, Blood.

[152]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[153]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[154]  Frank Diehl,et al.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.

[155]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[156]  A. Puisieux,et al.  Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  N. Santoro,et al.  Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma , 2005, Leukemia.

[158]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[159]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[160]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[161]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[162]  A. Puisieux,et al.  Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. , 2002, Cancer research.

[163]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[164]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[165]  L. Mologni.  Resistance mechanisms to ALK TKIs in tumors other than lung cancer , 2021 .

[166]  Veena Singh,et al.  Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer , 2018 .

[167]  D. Wong,et al.  Electric Field-Induced Disruption and Releasing Viable Content from Extracellular Vesicles. , 2017, Methods in molecular biology.

[168]  H. Groen,et al.  Investigating CTCs in NSCLC—a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer , 2016 .

[169]  J. Stebbing,et al.  Circulating free DNA in the management of breast cancer. , 2014, Annals of translational medicine.

[170]  Gemma K. Alderton.  Metastasis: Exosomes drive premetastatic niche formation , 2012, Nature Reviews Cancer.

[171]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.